Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07621718
Title field or adapter rule
{'original_value': 'RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:23.593298+00:00
Published At
2026-10-13T00:00:00+00:00
Record Updated At
2026-10-13
Source Retrieved At
2026-10-31T22:17:52.415050+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Pancreatic Cancer", "Pancreatic Cancer Metastatic", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-13", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT07621718"
protocolSection.identificationModule.officialTitle
"RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer Metastatic (protocolSection.conditionsModule.conditions)
  • PDAC (protocolSection.conditionsModule.conditions)
  • PDAC - Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Ductal Adenocarcinoma (PDAC) (protocolSection.conditionsModule.conditions)
  • Pancreatic Adenocarcinoma Metastatic (protocolSection.conditionsModule.conditions)
  • Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Adenosquamous Carcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Arm A: zoldonrasib + chemotherapy'], 'description': 'oral tablets', 'name': 'Zoldonrasib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm B: placebo + chemotherapy'], 'description': 'oral tablets', 'name': 'Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A: zoldonrasib + chemotherapy', 'Arm B: placebo + chemotherapy'], 'description': 'IV infusion', 'name': 'Oxaliplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A: zoldonrasib + chemotherapy', 'Arm B: placebo + chemotherapy'], 'description': 'IV infusion', 'name': 'Leucovorin (Calcium Folinate)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A: zoldonrasib + chemotherapy', 'Arm B: placebo + chemotherapy'], 'description': 'IV infusion', 'name': '5-Fluorouracil', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A: zoldonrasib + chemotherapy', 'Arm B: placebo + chemotherapy'], 'description': 'IV infusion', 'name': 'Irinotecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A: zoldonrasib + chemotherapy', 'Arm B: placebo + chemotherapy'], 'description': 'IV infusion', 'name': 'Gemcitabine (GEM)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A: zoldonrasib + chemotherapy', 'Arm B: placebo + chemotherapy'], 'description': 'IV infusion', 'name': 'Nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • Zoldonrasib (protocolSection.armsInterventionsModule.interventions[].name)
  • Placebo (protocolSection.armsInterventionsModule.interventions[].name)
  • Oxaliplatin (protocolSection.armsInterventionsModule.interventions[].name)
  • Leucovorin (Calcium Folinate) (protocolSection.armsInterventionsModule.interventions[].name)
  • 5-Fluorouracil (protocolSection.armsInterventionsModule.interventions[].name)
  • Irinotecan (protocolSection.armsInterventionsModule.interventions[].name)
  • Gemcitabine (GEM) (protocolSection.armsInterventionsModule.interventions[].name)
  • Nab-paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.